Pharvaris NV Ordinary Shares PHVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
-
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
-
Pharvaris Presents Data at the Bradykinin Symposium 2024
-
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
-
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Pharvaris Says FDA Lifted Clinical Hold on Application for Deucrictibant
-
Pharvaris shares surge as treatment for severe swelling meets clinical trial goal
Trading Information
- Previous Close Price
- $18.89
- Day Range
- $18.10–19.09
- 52-Week Range
- $15.00–33.00
- Bid/Ask
- $18.34 / $18.66
- Market Cap
- $1.00 Bil
- Volume/Avg
- 53,157 / 86,458
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 82
- Website
- https://www.pharvaris.com
Comparables
Valuation
|
Metric
|
PHVS
|
PHARM
|
QURE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.81 | 2.56 | 2.55 |
Price/Sales | — | 2.30 | 8.83 |
Price/Cash Flow | — | 98.52 | — |
Price/Earnings
PHVS
PHARM
QURE
Financial Strength
|
Metric
|
PHVS
|
PHARM
|
QURE
|
|---|---|---|---|
Quick Ratio | 18.14 | 2.65 | 6.61 |
Current Ratio | 18.45 | 3.39 | 7.36 |
Interest Coverage | — | −2.21 | −3.84 |
Quick Ratio
PHVS
PHARM
QURE
Profitability
|
Metric
|
PHVS
|
PHARM
|
QURE
|
|---|---|---|---|
Return on Assets (Normalized) | −35.77% | −4.16% | −31.33% |
Return on Equity (Normalized) | −37.92% | −8.62% | −121.03% |
Return on Invested Capital (Normalized) | −39.33% | −4.69% | −66.72% |
Return on Assets
PHVS
PHARM
QURE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jygscfxxwg | Xfh | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Blltgbns | Tsxsn | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pyfkxwltm | Jyxqptp | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ylfdhlfc | Kwtlxxq | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Swspcxdz | Xfbm | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rllfpnp | Fmb | $28.1 Bil | |||
| Moderna Inc
MRNA
| Mtqhcmw | Hbqr | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Ftlvclsg | Mgbxg | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dqwsvhkzj | Cvtmft | $13.4 Bil | |||
| Incyte Corp
INCY
| Zhdhlyzn | Gxjwgkh | $12.7 Bil |
United States